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In Europe, 1–3% of the population suffers from atrial fibrillation (AF) and has increased stroke risk. By 2060 a doubling in number
of cases and great burden in managing this medical condition are expected. This paper offers an overview of data on epidemiology
and management of AF and stroke in four European countries as well as the interconnection between these dimensions. A search
index was developed to access multiple scientific and “grey” literatures. Information was prioritised based on strength of evidence
and date. Information on country reports was double-checked with national experts. The overall prevalence of AF is consistent
across countries. France has the lowest stroke incidence and mortality, followed by Netherland and UK, while Romania has higher
rates. GPs or medical specialists are responsible for AF treatment; exception are the special thrombosis services in the Netherlands.
Prevention measurements are only present in UK through screening programs. Although international and national guidelines are
available, undertreatment is present in all countries. Despite differences in healthcare systems andmanagement of AF, epidemiology
is comparable between three of the countries. Romania is an outlier, by being limited in data accessibility. This knowledge can
contribute to improved AF care in Europe.
1. Introduction
Atrial Fibrillation (AF) is a common form of heart rhythm
disorder (arrhythmia). In Europe, AF is detected in 1-2% of
the population and is age-dependent, increasing in the elderly
[1–7]. AF is mostly asymptomatic, but due to the improper
flow of blood and the appearance of blood clots, it has acute
risk factors such as stroke [4–6, 8]. Figure 1 presents the
healthcare path of AF medical condition. Without special
detection programs, stroke is, in many cases, the first sign of
AF [3, 9]. The risk of a blood clot can be assessed using the
CHA
2
DS
2
-VASc score and the treatment for blood clots and
stroke prevention is done using oral anticoagulation (OAC)
treatment [10]. Most commonly used OAC drugs in the
treatment of detected AF are Vitamin K Antagonists (VKA)
orNewOral Anticoagulants (NOAC) [2, 3, 9]. Overtreatment
(taking OAC treatment without needing it, CHA
2
DS
2
-VASc
score 0 or 1) and undertreatment (not taking OAC treatment
when needing it, CHA
2
DS
2
-VASc score > 1) are frequent
[3, 8, 9, 11]. Undertreatment with OAC drugs on the longer
term causes severe and costly complications, such as stroke
(see Figure 1). Overtreatment can also have severe and costly
consequences such as bleeding. Overall, AF patients have a
fivefold higher risk of developing stroke [4, 6, 12]. The most
frequent stroke type in AF patients is ischemic stroke (IS),
which is connected to higher death rates or worse prognosis
at higher cost [4, 13].
Theheaviest burden inmanaging and treatingAFpatients
is the predicted doubling in number of patients suffering from
AF [5, 7, 12]. In addition to the growing number of newmed-
ical cases and increased risk of stroke in AF patients, there
is another challenge, namely, the large discrepancy between
and within countries in management and outcome of AF
patients [8, 9, 12, 14, 15]. These differences in management
of the medical condition, despite the existence of communal
guidelines for AF management [1, 2, 16, 17], reveal unequal
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Figure 1: Healthcare path of AF medical condition.
access to AF treatment for patients with the same health
conditions within Europe [8]. All these challenges on treating
andmanaging the AF patients havemajor public implications
and high increase in costs in the long-term [7, 8].
In order to reduce the burden of AF management and
prevent stroke at international level, it is essential to have
actual knowledge of the AF data in the different countries
[15].This paper aims to bring forward this type of information
by offering a collection of data on epidemiology andmanage-
ment of AF and stroke in several European countries.
Although numerous studies offer an overview on epi-
demiology of AF and stroke in different countries [14, 18–20]
or on the management of AF medical condition [2, 3, 12, 14,
21, 22], this paper brings a unique perspective. It brings an
original and complete review of available literature on both
epidemiology and management of AF and stroke in different
countries and indicates the interconnection between the two
dimensions.The scope of this paper is (1) to undertake a nar-
rative review of literature on available data and (2) to
offer a descriptive analysis (on magnitude) of the most
recent (by recent we mean information from our literature
study with the time window 2005–2016) and trustworthy
(by trustworthy we mean official healthcare organizations
and international journal publications) available data on the
epidemiology and management of AF and stroke in four
different European countries.
Countries in Focus. The focus of this paper is on four parti-
cular European countries: United Kingdom, France, Nether-
lands, and Romania. The choice of the countries has been
made in order to consider (1) different type of countries (as
geographic placement and economic level) as well as (2) diff-
erent type of health care systems and organization of the
medical care.
These countries can also be seen as prototypes for the
other countries in their region, with the UK for west Euro-
pean countries and RO for the East European ones and NL
for the north and FR for the south European countries. In
addition, the organization of the health care system in each
of these countries was considered. In what follows, we pre-
sent the type of healthcare system (tax based versus insura-
nce based; regionalized/decentralised versus centralized hea-
lthcare system) and role of the GP in the organization of care
(functions as a gatekeeper, yes or no) for each country in
focus.
In the UK, the public healthcare system provides free of
charge healthcare, with easy access for all permanent resi-
dents to primary care (general practitioner). Although the
National Health Service (NHS) covers four different coun-
tries (England, Scotland, Wales, and Northern Ireland), it is
a universal system that emphasises on Predictive, Preventive,
and Personalized Medicine elements [23]. This system is the
responsibility of the government and it is largely tax funded;
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it is a patient-centred system based on need instead of ability
to pay. In UK, GPs function as gatekeepers and they regulate
and coordinate primary and secondary medical care [23].
In contrast, the French healthcare system is based on the
Bismarckianmodel with influence from the Beveridge model
[24]. The main characteristics of the French decentralised
healthcare system are the high level of population health, the
degree of freedom for physicians and patients, the absence of
waiting lists for treatment, and the universal coverage [25].
The accessibility to the health care in France makes the role
of the GP as gatekeeper not extremely strong; population has
the opportunity to access specialized care directly for a higher
cost than with prescription from the GP [26].
Regarding the Netherlands, this small country has a
unique and innovative centralized healthcare system as a
consequence of the 2006 healthcare reform. This system is
based on a single compulsory healthcare insurance scheme.
For both providers and insurances, managed competition is
the main driver of the healthcare system; GPs function as
gatekeepers to the system and patients are in principle free
to choose their insurer and providers of care [27].
Finally, Romania is a large East European country with a
former communist background; it has a lower economic level
than the countries presented above. The previous Semashko
health system has yet to be fully developed in the long period
of democratic transition. In the process of decentralisation of
the system, numerous healthcare reforms took place due to
the political, social, and economic changes.The health system
is tax based and GPs function as gatekeeper. However, Roma-
nia has an overall poor health status with a life expectancy
lower and infant mortality higher than the average European
rate [28].
2. Methods
This paper offers a narrative review of the literature on
AF and stroke. The search of literature has been done per
country, using a specially developed topic index. The order
of the countries in the research is as follows: France, UK,
the Netherlands, and Romania. The search of data combined
different sources of information: (1) scientific literature, (2)
“grey” literature including governmental reports and natio-
nal/regional working documents, and (3) websites and data-
bases of different (inter)national healthcare organizations.
Table 1 names the literature sources used per country.
A specially designed topic index was used by first author
in order to extract data per country.The search index includes
terms on epidemiology of AF and stroke, and management
of AF with OAC treatment (see Figure 2). Full disclosure of
the search strategy and examples of the keywords used in
the search are presented in Appendix. The epidemiological
data considered are prevalence and prevalence prognosis of
AF, incidence of AF, stroke incidence, and mortality due to
stroke. Although AF is mainly associated with IS, we focused
on general stroke data, as no heterogeneity between studies
in IS data was found. The domains in the management of
AF considered are organization of treatment, medication,
available guidelines, level of undertreatment, and detection
rate.
Epidemiology
of AF and stroke
Management
of atrial brillation
(i) Prevalence of AF
(ii) Prevalence prognosis
(iii) Incidence of AF
(iv) Stroke incidence
(v) Mortality due to stroke
(i) Organization of AF treatment
(ii) AF medication with OAC
(iii) Available guidelines
(iv) Undertreatment with OAC
(v) Detection rate
Figure 2: Interconnection dimensions in focus.
The index terms were researched in English language
per country, for the time window 2005–2016, using diff-
erent search engines: PubMed, SAGE, BMG, ScienceDirect,
Global Health Data Exchange, Oxford University Press Jour-
nals/Europace, Research Gate, and Google (Scholar). As
such, specialized international AF Journals such as American
Hearth Journal, European Hear Journal, Journal of Cardiol-
ogy, Stroke, Heart Journal, and Chest Journal were included
in the search. Besides, the “grey” literature was consulted,
including governmental reports and national/regional work-
ing documents for each of the countries (in their domestic
language). In addition to the literature presented above,
websites and databases of the different national and interna-
tional healthcare organizations (in their domestic language)
were used in order to supplement the missing data. Where
country specific data was not found available, the research
was enlarged to regional studies or clustered country studies
for data enrichment. This strategy was especially used for
the epidemiology and management of AF in Romania where
published information is limited. Full disclosure of the search
strategy is available in Appendix.
In order to be used, all relevant research findings have
been prioritised based on two criteria: (1) themost recent data
and (2) the strength of evidence (trustworthiness of sources).
These two criteria functioned also as criteria for exclusion of
some data over the other. The time interval set for this litera-
ture review is from 2005 till beginning of 2016, with recent
data (cross-checked between articles) having priority. The
most trustworthy sources of information considered were
official healthcare organizations and international journal
publications.
After collecting the data per country, these were checked
and enhanced with comparative literature from studies on
multiple countries/regions. For example, due to limited infor-
mation available on Romania, the specific data was verified
and enriched with information from studies on East Euro-
pean countries.
Around 300 articles met the initial inclusion criteria for
all the four countries. From these around 100 articles were left
after the first exclusion (based on relevance of title, abstract)
and 50 after the second exclusion (based on full text and
check of duplicate). After full reading of text by first author,
a selection was done (based on usability of the data and
study settings design) and in the end 30 articles were used
as reference for the four countries in focus (see Table 1).
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In the last phase of the research, the country specific
reports have been double-checked for consensus with regard
to the data authenticity and validity with professional experts
from each country (see acknowledgments). Professionals
were asked to assess whether the data in the country report
represented the most actual and most correct data. These
national experts have been chosen based on their background
in AF and stroke awareness at national level, and/or their
collaboration with the eMbrace Institute foundation. Unfor-
tunately, no double-check of data was possible for Romania;
although different persons and organizations were accessed,
no national professional could be approached in this respect.
3. Results
The results of this literature study offer a collection of data
on epidemiology and management of AF medical condition
in patients who take or do not take OAC treatment in order
to prevent stroke in four European Countries (UK, F, NL,
and RO). This paper considers any type of OAC treatment
available in the countries in focus (either VKA or NOAC).
Tables 2 and 3 present condensed data of the four countries
per domains of consideration, on epidemiology andmanage-
ment, respectively.
3.1. Epidemiology. This section includes the epidemiological
data of AF medical condition and stroke, namely, prevalence
and prevalence prognosis of AF, incidence of AF, stroke
incidence, and mortality due to stroke.
The prevalence and prevalence prognosis of AF are
meaningful values since they report the number of cases as
a fraction of the whole population. The incidence of AF and
the incidence of stroke report the rate of new diagnoses cases
as a fraction of the population at risk.
In what follows each of the epidemiological aspects of AF
and stroke will be presented one by one.
3.1.1. Prevalence and Prevalence Prognosis. Prevalence of AF
is reported in the literature in many specific study settings or
patient groups.Althoughprevalence differs per age group and
gender, the overall AF prevalence in the UK, France, and the
Netherlands is consistent at ∼1,5% [7, 29, 30] with the lowest
values in NL [7]. By the year 2050, in the European Union
a doubling of the AF cases is expected, especially due to the
aging of the population [7, 30].
3.1.2. Incidence. Incidence of AF also varies with age group.
For example, in NL are reported 1.1 per 1000 person years
in age group 55–59 and 18.2 per 1000 person years in age
group 80–84 [13]. In UK the incidence of AF is estimated
to be between 1.7 and 3 per 1000 person years [31], while in
FR a little lower, at approximately 1.1 to 2.3 per 1000 per-
son years [32]. From our knowledge, no data is available
on the incidence and prevalence of AF in RO. Variation of
reported AF incidence should be read with some caution as
the difference between countries can largely be explained by
the difference in study reported groups.
3.1.3. Stroke Risk and Mortality. AF in general causes a
fivefold rise in stroke risk [6, 12]. AF is mostly associated with
IS which brings more complications and poorer prognosis
than other types of stroke [13, 32]. Around 25% of the causes
of all stroke are connected to AF [6]. As no heterogeneity
between studies in IS data was found, we looked into general
stroke data. The WHO estimates on stroke incidence are the
lowest in FR (number 1 in Europe), followed by NL and UK
[20]. Eastern European Countries (Romania included) have
the highest risk of stroke in Europe [22].
Mortality due to stroke follows the same sequence as
stroke incidence, with the lowest rate in FR (31 per 100,000
persons) followed by NL (35 per 100,000 persons) and UK
(42 per 100,000 persons) [33]. The East European countries
in general (nonspecific for Romania) have higher stroke
mortality rates. These mortality rates in Eastern Europe are
increasing in number lately, while in the Western European
countries there is a decline in stroke mortality [20, 33].
3.2. Management. In the management of AF medical con-
dition for the countries in focus we considered five aspects:
organization of treatment; medication used in the treatment
of AF (either VKA or NOAC); available guidelines used in
the management of the disease; level of undertreatment; and
detection rate programs for AF and stroke prevention. In
what follows each of the management aspects will be presen-
ted one by one.
3.2.1. Organization of Treatment. Organization of AF treat-
ment is different in each of the countries, resulting in differen-
tial treatment for patients with the same health care condition
within Europe [22]. The situation of the four countries in
focus is presented hereunder.
In UK, the national structured healthcare system, NHS,
includes implicitly the management of AF patients with OAC
treatment. The GP has a 100% implication in AF patient
treatment, with no special anticoagulation clinics for the
management of AF medical condition. With more than 10%
of the patients over 65 years old suffering from AF, GPs have
an intensive task to deal with the identification as well as
the management of AF on a regular bases [34]. The NICE
guideline on AF builds explicitly on the relationship between
GPs and their patients for a clear management plan which
takes into account the patient’s personal preferences and the
clinician’s view of evidence [35].
France has decentralised organization and management
of OAC treatment. In France, patients suffering from AF are
either seen by general practitioners or general cardiologists
[36]. The result of three pooled cross-sectional studies in
France shows that the number of GPs giving care to AF
patients is almost twice as high as the number of cardiolo-
gists (5,553 GPs and 3,189 cardiologists) [37]. There are no
specialized anticoagulation clinics in France, but access to
laboratories and doctors is quite easy [37].
Romania also has a decentralised organization of treat-
ment; no special clinics are available. In general, patients
with AF are detected by GPs and directed for treatment and
follow-up to the medical specialist, generalist, or cardiologist
responsible for managing and prescribing OAC treatment
[38].
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In contrast to these three countries, the decentralised org-
anization and execution of OAC treatment in NL is done
through specialized outpatient clinics named “trombosedien-
sten” (thrombolysis services). These clinics (53 in total) are
responsible for the management and dosing of OAC treat-
ment (VKA treatment) in AF patients [39, 40]. Initially,
patients are diagnosed by GP or cardiologist based on clinical
examination, patient history, and ECG [41].
3.2.2.Medication. RegardingAFmedication, nonational stu-
dies on the use of one OAC treatment over the other (VKA
or NOAC) are available in the countries in focus. However,
regional studies show that the predominant treatment of AF
patients is the traditional vitamin K treatment, the VKA.
Nevertheless, it should be considered that wide geographical
differences could exist. A recent study from the UK shows
that 75% of the patients are treated with VKAwhile in France
86% [42]. NOAC is the new alternative to VKA and entered
the market of all countries in 2012. This latest medication
experiences a rapid increase in number of uses especially in
the younger patients [2].
3.2.3. Available Guidelines. Guidelines of AF management
have an important role in providing medical practitioners
with regulations for the best treatment of AF patients, con-
sidering the outcome and risk-benefit ratio. Also, guidelines
provide equal treatment possibilities for patients with similar
medical conditions across Europe. The “Guidelines for the
management of atrial fibrillation” from the Task Force for
Management of Atrial Fibrillation of the European Society of
Cardiology (ESC) 2010/2006 [1, 16] are communal guidelines
provided by the European Society of Cardiology which are
available in all of the countries in focus. Also the new “2016
European Guideline on cardiovascular disease prevention
in clinical practice” is expected to be adopted in all of the
countries [17].
Next to this international guideline, there are also natio-
nal guidelines available in all of the countries. In France,
there are the “Guide Pratique d’E´laboration: Protocoles pluri-
professionnels des soins de premier recours Exemple ges-
tion quotidienne des AVK” (PPSPR) Nov. 2011 and “Guide
Parcours Arcours de Soins: Fibrillation Atriale” (HAS) from
February 2014; in the UK there are the NICE clinical guide-
lines from 2006 and 2014; in the Netherlands there is a guide-
line available for the GP, from the “Nederlands Huisartsen
Genootschap” (NHG), and there is a guideline from the
“Kwaliteitsinstituut voor de Gezondheidszorg” (CBO). Car-
diologists in NL use the ESC guideline and a specific “lei-
draad” (manual) for the NOAC introduction.
3.2.4. Undertreatment. Undertreatment, as explained earlier,
considers the cases of AF patients in need of OAC treatment
(CHA
2
DS
2
-VASc score > 1) that do not benefit from the
medication, having great medical implications and raising
the risk of stroke [3, 11]. Although undertreatment with OAC
drugs differs per study/age group, this phenomenon is present
in all countries [3, 9, 11, 31].The lowest level of undertreatment
is reported in the Netherlands (18%) particularly in elderly
[41, 43], and the highest is in East and SouthEurope (Romania
included) [9, 44]. Recent studies in UK and FR also show
high degrees of undertreatment [31, 37]; around half of the
detected stroke patients with AF eligible for OAC treatment
do not receive it, although there is proven efficiency of OAC
treatment in stroke prevention [45–47].
3.2.5. Detection Rate. At the same time, between a third and
a half of patients affected by AF are not detected in time
but are discovered in a complicated or fatal phases [47].
Several strategies of AF detection and diagnosis are present
in UK at national level, where GPs function as gatekeepers.
Through these programs, screening of irregular pulse check
is followed by recommended electrocardiography (ECG) on
all suspected AF patients (symptomatic or not) [48]. In UK,
patients aged >65 are all screened based on pulse taking
(eventually followed by ECG), as a systematic screening
programme [49]. In FR, NL, and RO no special programs
are known for the detection of AF patients in order to reduce
stroke risk. Case finding in these countries is done randomly,
when patients present themselves to the medical doctor with
symptoms [13, 37].
4. Discussion
Knowledge of data in the different countries is desirable
since it can contribute to reduced burden of AF management
and improved medical condition of AF patients through
stroke prevention in different countries.This is the first paper
to undertake a review of available data on epidemiology
and management of AF and stroke in these four European
countries (UK, FR, NL, and RO). Learning from one another
at national level and preventing stroke by fighting against
undertreatment with OAC drugs in AF patients can diminish
the expected burden of AF management.
4.1. Epidemiology. This paper shows similarities in epidemi-
ological data between some of the countries in focus (UK,
F, and NL). One resemblance in data is the prevalence of
AF medical condition, which is affecting ∼1,5% of the total
population. These results are consistent with the findings
from other European studies such as Camm et al. 2010 [1] but
new compared to the world-wide study of Lip et al. 2010 [18]
where high variation in AF prevalence is found.
The growth in prevalence of AF is another topic of resem-
blance. By the year 2050, the number of people suffering from
AF is expected to increase by three times in USA [50] and by
two times in Europe [7, 18, 29, 51]. A study by Krijthe et al.
reports a lower prognosis ofAFprevalence in theNetherlands
compared with EU in general. The number of individuals
with AF will more than double, to a peak of about 553,700
in the year 2050, and then decrease slightly to 547,700 in the
year 2060 reflecting 3.2% of the Dutch population [7]. An
explanation to this alarming prevalence prognosis estimate
is connected to the aging of the population over the age of 55
[7]. This aspect is of real importance since with the growing
number of cases the burden of managing the AF medical
condition becomes even higher.
The highest difference in epidemiological data between
countries is met in reported AF incidence.The highest values
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are registered in NL, with an overall rate of 9.9/1000 person
years in a population over 55 years.The encountered variation
in values is considered to originate from different sources of
case reports considered (hospital based survey, community
based studies, clinical trials, etc.), as well as from the different
age groups in the study population. However, the use of the
different incidence values should be used with caution.
As a general trend, patients suffering from AF face inc-
reased risk of stroke and more severe and costly complica-
tions [13]. In UK, FR, and NL the stroke incidence estimates
are between the lowest 10 in Europe [20]. It is hypothesized
that the lowest level of stroke, which is reported in France, is
connected to diet and lifestyle [19]. Although the incidence of
stroke is also reflected in the level of mortality due to stroke,
we believe that these cases could be prevented or diminished
through better AF case identification and in time treatment
with OAC drugs.
Romania is an outlier by being limited in epidemiological
data and access to medical information. The lack of data and
incomplete medical records encountered in Romania have
different reasons. On the one hand, there is a lack of under-
standing of the potential benefits of data registration of AF
patients and stroke cases [15]. On the other hand, there is an
overall shortage of qualified professionals and lack of incen-
tive in data registration, although the infrastructure and the
modernpublic health information resources are available [52].
4.2. Management. In the management of AF medical condi-
tion, there are similarities to a certain degree despite the dif-
ferent organizations of treatment andAF detection programs.
The similarities are inmedication, guidelines, and presence of
undertreatment with OAC drugs.
In three of the countries the GP or medical specialist/
cardiologist is responsible for diagnosis, treatment, andmon-
itoring of AF patients. Unlike the other countries, theNether-
lands has special local anticoagulation clinics for AF patients.
These regional outpatient clinics are responsible for the
management of care and dosing of AF treatment. The Dutch
example of management of AF patients could be related to
a lower level of undertreatment and improved therapies in
stroke prevention in AF patients [18].
The reported presence of undertreatment with OAC
drugs in AF patients in the different countries [3, 11, 43] has
multiple and costly complications, especially in the ones with
elevated risk of stroke [3, 8]. In addition, another special
group known to be more prone to undertreatment with OAC
drugs are the elderly [21]. In literature, the level of undertreat-
ment is associated with nonadherence to guidelines [9, 53].
Interestingly enough, the ESC 2006 or 2010 guideline is
available in all the countries in focus.Next to the international
guidelines, there are also national guidelines available inmost
countries. However, the level of undertreatment is still sig-
nificant in all the countries [3, 11, 31], with the lowest reported
values in the Netherlands [41, 43]. This result could be
explained by the different model of organization of treatment
for AF patients in this county, and by the usability of the avail-
able guidelines [53].
Another issue that plays an important role in stroke pre-
vention is the detection of AF patients at a prior stage. Since
AF is a silent disease, mostly asymptomatic, detection pro-
grams are important to be done systematically at population
level. From the countries in focus, only UK stands out with
a special screening program for AF detection, implemented
at national level. Intriguingly, better detection of AF cases in
UK is not reflected in lower levels of undertreatment, or a
reduced number of strokes and less mortality in comparison
to the other countries. This issue is considered to be a topic
for further study.
Romania remains an outlier in access to information, also
onmanagement and treatment strategy.The data onRomania
has been enhanced with information from studies on East
European countries (Romania included).
4.3. Strengths and Limitations. An advantage of this literature
study is that it goes beyond the standard review methods
by using multiple sources of information such as scientific
literature, “grey” literature, and national and regional docu-
ments; the information was searched in English as well as the
other national languages. The data was prioritised based on
date and trustworthiness of the sources. In order to assess the
authenticity and validity of the data, the reports of each of the
countries have been double-checked with national experts.
Unfortunately, although numerous attempts were initiated
to access a national expert in Romania, no professional was
available to double-check the country report. This attitude
could be the effect of crowded timetables for the professionals
or lack of actual knowledge of the severity of AF problem in
Romania.
A drawback of this study is that the data used comes
from different sources and studies. This makes a comparison
between the four countries challenging, since there are mul-
tiple study settings, designs, sample sizes, and different time
intervals.
Furthermore, attention should be given to the fact that
although the healthcare problempresented in this paper is the
same for all the different countries, the national registrations
and the awareness of acting on the AF condition differ per
country.This could have consequences for the actual registra-
tion and availability of the data.
Since this paper is based on a narrative literature review
and offers a descriptive analysis (on magnitude) of available
data on epidemiology and management of AF, no statistical
analysis or meta-analysis were planned or executed. As such,
this paper provides the reader with an up-to-date collection
of information on epidemiology and management of AF
and stroke in four European countries (NL, UK, FR, and
RO). These four countries could represent prototypes for the
AF epidemiology and management of the other European
countries. In this way, the results are illustrative for a broader
range of countries and the information provided in this study
could be used in order to lower the expected burden of AF
management and improve medical condition of AF patients
through stroke prevention in the different countries.
5. Conclusion
This paper brings knowledge on the epidemiology and
management of AF in four European countries: the UK,
10 Stroke Research and Treatment
France, the Netherlands, and Romania. The healthcare sys-
tem and management of AF is different between countries.
However, these differences are not reflected in the reported
epidemiological data of three of the four countries (UK,
F, and NL). Romania is an outlier by being limited in the
availability and accessibility of data.Whether the same trends
and principles also apply to other East European countries
would be a subject for further study.
These differences in management of the medical condi-
tion prove unequal access to AF treatment for patients with
the same health conditions within Europe, despite the existe-
nce of communal ESC guidelines.The growing number of AF
patients combined with the discrepancies in AFmanagement
and access to AF treatment lead to a heavy burden for the
medical system and increased cost in the long-term.
Recommendations. Knowledge of data in the different coun-
tries can contribute to a reduced burden of AF management
and improved medical condition of AF patients through
stroke prevention. Using the example of the Netherlands in
the organization of treatment through specialized anticoagu-
lation clinics could result in a lower level of undertreatment
and improved programs of stroke prevention. Also, the UK
national program of AF detection is a desirable strategy of
stroke prevention to be used in the other countries.
Practical recommendations based on this paper would be
standardization of the systems with regard to organization
of the AF treatment, as well as matching measurements and
registries, which prove to be so necessary. In this regard,
the presence of a communal clinical guidelines, as the
ESC guideline, is a step forward, but action for a practical
implementation and use of guidelines is also needed. All
in all, learning from one country to the other could offer
benefits.
Appendix
Literature Search Strategies
The search of literature has been done per country and topic
index.The order of the countries in the research is as follows:
France, the UK, the Netherlands, and Romania. The study of
France considered the largest search index: (1) epidemiology
of atrial fibrillation (AF) and stroke, (2) management of
AF and use of oral anticoagulation drugs (OAC) as well as
stroke prevention strategies, and (3) costs associated with
AF and OAC treatment. Due to difficulties in accessing and
processing data on costs within and between countries, this
section has been taken out of the current study.
The search index on epidemiology included prevalence
AF, prevalence prognosis, incidence of AF, incidence ischemic
stroke (IS), incidence of IS due to AF, incidence of IS in
AF patients who take OAC treatment, and mortality due to
stroke. The management section considered the following
topics: organization of treatment, medication, guidelines used
for management of AF, guidelines used for OAC treatment and
IS prevention, undertreatment, and detection rate.
Although AF is mainly associated with IS, this study
could not include this data due to the lack of heterogeneity
in the available studies. However, the incidence of stroke
in general and mortality due to stroke were taken into
consideration. Other data not included in the final paper due
to heterogeneity problems are incidence of IS due to AF and
incidence of IS in AF patients who take OAC treatment.
Several topics were compressed due to similitudes under
an umbrella topic. For example guidelines used for manage-
ment of AF and guidelines used for OAC treatment and IS
prevention were grouped in available guidelines.
The search strategy used in PubMed, SAGE, BMG,
ScienceDirect, Global Health Data Exchange, Oxford Uni-
versity Press Journals/Europace, Research Gate, and Google
(Scholar) included the country in focus and each of the
keywords from the search index presented above, for
example, ⟨FranceANDepidemiologyANDatrial fibrillation⟩,
then ⟨FranceAND“incidence atrial fibrillation”⟩, then
⟨FranceAND“incidence ischaemic stroke” OR “incidence
ischemic stroke”⟩, and then ⟨FranceAND“strokemortality”⟩.
The search terms were searched in all fields (title, abstract,
keywords, and text). The search was limited to the time
period 2005–2016. Around 300 articles met the initial
inclusion criteria. From these around 100 articles were left
after the first exclusion (based on relevance of title, abstract)
and 50 after the second exclusion (based on full text and
check of duplicate). After full reading of text a selection
was done (based on usability of the data and comparison of
study settings) and 30 articles were used as reference to this
literature review.
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